• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Palisade Bio Inc.

    12/13/24 9:57:40 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PALI alert in real time by email
    POS AM 1 formposam.htm

     

    As filed with the Securities and Exchange Commission on December 13, 2024.

     

    Registration No. 333-282883

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    Post-Effective Amendment No. 1

    to

    FORM S-1

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Palisade Bio, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware   2834   52-2007292
    (State or Other Jurisdiction of
    Incorporation or Organization)
      (Primary Standard Industrial
    Classification Code Number)
      (I.R.S. Employer
    Identification Number)

     

    Palisade Bio, Inc.

    7750 El Camino Real, Suite 2A

    Carlsbad, CA 92009

    (858) 704-4900

    (Address, including zip code, and telephone number, including area code of registrant’s principal executive offices)

     

     

    Paracorp Incorporated

    2140 S Dupont highway

    Camden, DE 19934

    (302) 697-4590

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    Raul Silvestre, Esq. Michael Nertney, Esq.
    Dennis Gluck, Esq. Ellenoff Grossman & Schole LLP
    2629 Townsgate Road #215 1345 Avenue of the Americas
    Westlake Village, CA 91361 New York, NY 10105

     

     

    Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. ☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
           
    Non-accelerated filer ☒ Smaller reporting company ☒
           
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

    This registration statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(d) of the Securities Act of 1933, as amended.

     

     

     

     
     

     

    EXPLANATORY NOTE AND INCORPORATION BY REFERENCE

     

    This Post-Effective Amendment No. 1 (this “Amendment”) relates to the Registrant’s Registration Statement on Form S-1 (File No. 333-282883), initially filed by the Registrant on October 30, 2024, as amended (the “Registration Statement”), and declared effective by the Securities and Exchange Commission on December 12, 2024. The Registrant is filing this Amendment pursuant to 462(d) for the for the purpose of (i) replacing Exhibit 5.01 to the Registration Statement and (ii) including Exhibit 10.50.

     

    EXHIBIT INDEX

     

    Exhibit Number   Description of document
    5.01*   Opinion of Silvestre Law Group, P.C.
    10.50*   Form of Warrant Letter Agreement.
    23.2*   Consent of Silvestre Law Group, P.C. (included in Exhibit 5.01).
    24.1   Power of Attorney (incorporated by reference to the signature page of the prior registration statement on Form S-1 (File No. 333-282883), filed with the Securities and Exchange Commission on October 30, 2024, and incorporated herein by reference).

    * Filed herewith

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Carlsbad, State of California on December 13, 2024.

     

      Palisade Bio, Inc.
         
      By: /s/ J.D. Finley
        J.D. Finley
        Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Carlsbad, State of California on December 13, 2024

     

    Signature   Title   Date
             
    /s/ J.D. Finley   Chief Executive Officer and Director   December 13, 2024
    J.D. Finley   (Principal Executive Officer)    
             
    /s/ J.D. Finley   Chief Financial Officer   December 13, 2024
    J.D. Finley   (Principal Financial and Accounting Officer)    
             
    *   Chairman of the Board and Director   December 13, 2024
    Donald A. Williams        
             
    *   Director   December 13, 2024
    Binxian Wei        
             
    *   Director   December 13, 2024
    Margery Fischbein        

     

    *By: /s/ J.D. Finley  
      J.D. Finley  
      Attorney-in-Fact  

     

     

    Get the next $PALI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PALI

    DatePrice TargetRatingAnalyst
    2/2/2022$5.00Buy
    Ladenburg Thalmann
    8/31/2021$7.00Buy
    Maxim Group
    More analyst ratings

    $PALI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Williams Donald Allen bought $4,863 worth of Comon Stock (1,000 units at $4.86) (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      5/29/24 3:47:14 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Finley John David bought $4,810 worth of shares (1,000 units at $4.81), increasing direct ownership by 13% to 8,437 units (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      5/28/24 6:02:01 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Finley John David bought $4,692 worth of shares (10,000 units at $0.47), increasing direct ownership by 13% to 84,649 units (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      2/7/24 8:30:10 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PALI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Jones Mitchell Lawrence

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      2/13/25 5:58:18 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CEO, CFO Finley John David

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      2/13/25 5:56:42 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Wei Binxian converted options into 388 units of Comon Stock, increasing direct ownership by 83% to 855 units (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      11/22/24 4:00:10 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PALI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Palisade Bio Inc.

      SC 13G - PALISADE BIO, INC. (0001357459) (Subject)

      11/14/24 3:35:13 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Palisade Bio Inc. (Amendment)

      SC 13G/A - PALISADE BIO, INC. (0001357459) (Subject)

      2/14/24 2:54:03 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Palisade Bio Inc. (Amendment)

      SC 13G/A - PALISADE BIO, INC. (0001357459) (Subject)

      2/13/24 8:10:04 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PALI
    Leadership Updates

    Live Leadership Updates

    See more
    • Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

      Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) --  Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases, today announced the appointment of Brian G. Feagan, MD, FRCPC, to its Clinical Advisory Board. Dr. Feagan is a distinguished gastroenterologist with over 30 years of experience in the design, conduct, and execution of large-scale randomized controlled trials (RCTs) for Crohn's disease (CD) and ulcerative colitis (UC). He has served as Principal Investigator in more than 140 multi-center RCTs and has dedicated mu

      12/17/24 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio Appoints Margery Fischbein to its Board of Directors

      Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has appointed Margery Fischbein to its Board of Directors. Ms. Fischbein is a highly experienced healthcare investment banker and accomplished biotechnology industry executive. "We are excited to welcome Ma

      5/7/24 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Correction Notice of Palisade Bio's Press Release Announcing the Appointment of Clinical Advisory Board Members

      Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (NASDAQ:PALI) ("Palisade" or the "Company"), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced a correction to its press release originally issued on February 8, 2024, announcing the appointments of Bruce Sands, MD, MS and Florian Rieder, MD to its Clinical Advisory Board (CAB). In the original press release, it was incorrectly stated that the PALI-2108 development program was on track to commence a Phase 1 clinical study next year. The Company reiterates its guidance that the PALI-2108 Phase 1 clinical study is on track to launch in 20

      2/8/24 2:40:00 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PALI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

      Two posters presented at Digestive Disease Week (DDW) 2025 Preclinical results indicate that PALI-2108 effectively modulates inflammatory pathways in the colon, promoting a favorable immune response Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts Carlsbad, CA, May 06, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the presentation of positive preclinical data from

      5/6/25 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

      Carlsbad, CA, May 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it has been selected to give an oral presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit being held May 13–15, 2025 in Boston, MA. Details of the oral presentation are as follows: Session: Advancing AI-Driven Diagnostics & Enhancing Patient Monitoring to Personalize Treatment Decisions & Improve Long-Term Patient OutcomesTitle: Improving

      5/1/25 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

      Sustained positive preliminary data from all completed single ascending dose (SAD) cohorts, multiple ascending dose (MAD) cohorts, and food effects crossover, further supporting the safety and tolerability of PALI-2108 No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed to date Screening for Phase 1b UC cohort ongoing; On track to report topline data in the first half of 2025 Carlsbad, CA, April 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune,

      4/9/25 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PALI
    Financials

    Live finance-specific insights

    See more
    • Palisade Bio (Nasdaq: PALI) Announces Analysis Demonstrating LB1148 Reduced the Extent and Severity of Post-Surgical Intraabdominal Adhesions by 93%

      Data from Pooled-Analysis of Enteral Protease Inhibitor LB1148 Demonstrated 72% Reduction in the Risk of Adhesion Formation in Patients Undergoing Bowel Resection Surgery Company to Host Conference Call on Wednesday, March 16, 2022, at 8:30 a.m. EDT CARLSBAD, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced data from a Pooled-Analysis of Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN.) These data are featured today at the Next Big Thing session of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 202

      3/16/22 8:00:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PALI
    SEC Filings

    See more
    • Palisade Bio Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - PALISADE BIO, INC. (0001357459) (Filer)

      5/2/25 4:11:24 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Palisade Bio Inc.

      10-K - PALISADE BIO, INC. (0001357459) (Filer)

      3/24/25 4:20:12 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by Palisade Bio Inc.

      424B3 - PALISADE BIO, INC. (0001357459) (Filer)

      12/17/24 5:30:00 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PALI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ladenburg Thalmann initiated coverage on Palisade Bio with a new price target

      Ladenburg Thalmann initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

      2/2/22 7:38:44 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Maxim Group initiated coverage on Palisade Bio with a new price target

      Maxim Group initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

      8/31/21 8:02:44 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care